Table 3.

Subjects Who Withdrew from Treatment or the Study^*

Variable	Combination Therapy (N=140)	Sertraline (N=133)	Cognitive Behavioral Therapy (N=139)	Placebo (N=76)
	number (percent)
Withdrawal from treatment	1 (0.7)	7 (5.3)	0	3 (3.9)
Attributed to an adverse event	1 (0.7)	2 (1.5)	0	2 (2.6)
Tremor	0	1 (0.8)	0	0
Stomach pain	0	1 (0.8)	0	0
Suicidal ideation	0	0	0	1 (1.3)
Worsening symptoms	1 (0.7)	0	0	1 (1.3)
Other reason	0	5 (3.8)	0	1 (1.3)
Improved symptoms	0	0	0	1 (1.3)
Declined treatment	0	5 (3.8)	0	0
Withdrawal from study	12 (8.6)	16 (12.0)	6 (4.3)	12 (15.8)
Attributed to an adverse event	2 (1.4)	6 (4.5)	0	1 (1.3)
Agitation or disinhibition	1 (0.7)	2 (1.5)	0	0
Self-harm or homicidal ideation	0	1 (0.8)	0	0
Hyperactivity	0	1 (0.8)	0	0
Worsening symptoms	1 (0.7)	1 (0.8)	0	0
Headache	0	1 (0.8)	0	0
Rash	0	0	0	1 (1.3)
Other reason	10 (7.1)	10 (7.5)	6 (4.3)	11 (14.5)
Lack of improvement	2 (1.4)	0	1 (0.7)	1 (1.3)
Loss of contact	5 (3.6)	3 (2.3)	2 (1.4)	2 (2.6)
Time burden	0	0	1 (0.7)	1 (1.3)
Withdrawal of consent	3 (2.1)	7 (5.3)	1 (0.7)	6 (7.9)
Other	0	0	1 (0.7)	1 (1.3)

^*Subjects who withdrew from treatment stopped receiving their assigned therapy but continued to undergo assessment; those who withdrew from the study stopped receiving their assigned treatment and did not undergo continued assessment.